<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(1)</volume><submitter>Kumar A</submitter><pubmed_abstract>LC-MS and immunoassay can detect protein biomarkers. Immunoassays are more commonly used but can potentially be outperformed by LC-MS. These techniques have limitations including the necessity to generate separate calibration curves for each biomarker. We present a rapid mass spectrometry-based assay utilising a universal calibration curve. For the first time we analyse clinical samples using the HeavyPeptide IGNIS kit which establishes a 6-point calibration curve and determines the biomarker concentration in a single LC-MS acquisition. IGNIS was tested using apolipoprotein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD). Human serum and IGNIS prime peptides were digested and the IGNIS assay was used to quantify APO-F in clinical samples. Digestion of IGNIS p</pubmed_abstract><journal>Scientific reports</journal><pagination>12072</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5608892</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Absolute quantitation of disease protein biomarkers in a single LC-MS acquisition using apolipoprotein F as an example.</pubmed_title><pmcid>PMC5608892</pmcid><pubmed_authors>Cobbold J</pubmed_authors><pubmed_authors>Zitzmann N</pubmed_authors><pubmed_authors>Thursz M</pubmed_authors><pubmed_authors>Kumar A</pubmed_authors><pubmed_authors>Gangadharan B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Absolute quantitation of disease protein biomarkers in a single LC-MS acquisition using apolipoprotein F as an example.</name><description>LC-MS and immunoassay can detect protein biomarkers. Immunoassays are more commonly used but can potentially be outperformed by LC-MS. These techniques have limitations including the necessity to generate separate calibration curves for each biomarker. We present a rapid mass spectrometry-based assay utilising a universal calibration curve. For the first time we analyse clinical samples using the HeavyPeptide IGNIS kit which establishes a 6-point calibration curve and determines the biomarker concentration in a single LC-MS acquisition. IGNIS was tested using apolipoprotein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD). Human serum and IGNIS prime peptides were digested and the IGNIS assay was used to quantify APO-F in clinical samples. Digestion of IGNIS p</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Sep</publication><modification>2026-05-06T06:32:42.094Z</modification><creation>2019-03-27T02:57:04Z</creation></dates><accession>S-EPMC5608892</accession><cross_references><pubmed>28935895</pubmed><doi>10.1038/s41598-017-12229-2</doi></cross_references></HashMap>